|
IDH1 and IDH2 (Haematology)
|
|
General
|
| |
Clinical Use:
|
Mutations in IDH1 and IDH2 genes are found in approximately 20% of AML patients. IDH mutations are the target of IDH inhibitors currently in clinical trials. Bone marrow is the sample of choice as IDH1 and IDH2 mutations are present in AML blast cells, although blood can be tested if there is a high number of circulating blasts. False negatives may be reported if the population of cells carrying the IDH mutation and/or the number of blast cells are too few in the sample. The assay utilised for detecting IDH1/IDH2 variants is not a NATA accredited assay. |
| |
Availability:
|
Samples are tested Monday-Friday. |
| |
Aliases/Synonyms:
| IDH1 (Haematology), IDH2 (Haematology), |
| |
Code:
|
HIDH |
| |
Handling Instructions (to laboratory):
|
Send sample ambient. |
| |
Hyperlink:
|
|
| |
Reference Interval:
|
Results for IDH1 mutation studies are reported as detected or not detected
|
Collection Requirements
|
| |
Container:
|
EDTA (LAV9), |
| |
Sample Type:
|
Blood; Bone Marrow |
| |
Minimum Collection Volume:
|
|
| |
Collection Instructions:
|
|
Processing Requirements
|
| |
Alternate Containers:
|
|
| |
Processing Instructions:
|
Store sample at room temperature. |
| |
Minimum Assay Volume:
|
3mL Blood; 1mL Bone Marrow |
| |
Stability:
|
|
| |
Transport Instructions (to testing laboratory):
|
Send sample ambient. |
Testing Locations
|
| |
Performed at:
|
|
Section
|
Department
|
Site
|
Contact Phone
|
| Molecular |
Haematology |
Fiona Stanley Hospital |
6152 8118 |
|
Last Updated : 29-11-2021 17:18 |